• Lisa Lynn Wang, MD

    Wang Lisa

    Department or Service

    Department of Pediatric Medicine, Hematology-Oncology

    Specialty

    Hematology-Oncology

    Primary Location

    Texas Children's Hospital

    Contact Information

    6701 Fannin St.
    14th Floor
    Houston, TX 77030
    Get Map & Directions

    Phone: 832-824-4822
    Fax:  832-825-4276

    Director, Bone Tumors Program and Clinical Leader, Musculoskeletal Tumor Clinic - Texas Children's Cancer Center
    Associate Professor, Department of Pediatrics, Section of Oncology-Hematology, Baylor College of Medicine

    Medical School

    University of North Carolina at Chapel Hill, Doctor of Medicine, 1993

    Residency

    Children's Hospital of Los Angeles, Pediatrics, 1996

    Fellowship

    Baylor College of Medicine, Pediatric Hematology Oncology, 2001

    From Dr. Wang

    Dr. Lisa Wang is Director of the Bone Tumor Program and the Clinical Leader of the Musculoskeletal Tumor Clinic at Texas Children's Cancer Center. Dr. Wang has a special interest in sarcomas, particularly bone sarcomas such as osteosarcoma and Ewing's sarcoma.

    Dr. Wang is Director of the Bone Tumor Program (Osteosarcoma Program) at Texas Children's Cancer Center. The Bone Tumor Program brings together clinical and basic science researchers who are commonly investigating various aspects of osteosarcoma (OS) biology and treatment. The Bone Tumor Program promotes advanced research and clinical activities, which center around bone sarcomas, as part of the educational initiatives for hematology-oncology fellows and students.

    Dr. Lisa Wang is also the Clinical Leader of the Musculoskeletal Tumor Clinic, an interdisciplinary clinic within the Outpatient Clinic at Texas Children's Cancer Center. The Musculoskeletal Tumor Clinic brings together a team of clinical specialists to decide on management plans for patients with bone tumors. The team includes an orthopedic surgeon, a pediatric oncologist, a pediatric nurse practitioner, a solid tumor fellow, and a social worker, among other caregivers.

    Dr. Lisa Wang is a member of the Children's Oncology Group (COG) where she actively participates on the Bone Tumor Committee. Dr. Wang serves as the institutional Principal Investigator for the cooperative group randomized clinical trial for newly diagnosed Ewing's sarcoma patients (AEWS0031). She previously served as the Principal Investigator for the cooperative group trial to treat newly diagnosed OS patients (EURAMOS protocol).

    Dr. Lisa Wang's research interests includes the molecular pathogenesis of osteosarcoma. She specifically focuses on the RECQL4 pathway and Rothmund-Thomson syndrome (RTS), a rare, inherited disorder that predisposes affected individuals to developing osteosarcoma. Her research goals include:

    1. understanding the molecular basis of Rothmund-Thomdon syndrome and related disorders by studying the mechanisms that predispose individuals to cancer development;
    2. defining the clinical phenotype and appropriate medical management of these patients; and
    3. understanding the role of RECQL4 pathways in the pathogenesis of osteosarcoma and skeletal development.

    Dr. Lisa Wang is a member of the Solid Tumor Programs and the Bone Tumor Program.

    Clinical Specialties

    Sarcomas, particularly bone sarcomas (osteosarcoma, Ewing's sarcoma)

    Research Activities

    Molecular pathogenesis of osteosarcoma
    Rothmund-Thomson syndrome
    Role of RECQL4 pathways in the pathogenesis of osteosarcoma and skeletal development

    Professional Organizations

    • American Association for Cancer Research
      Member
    • American Society of Clinical Oncology
      Member
    • American Society of Pediatric Hematology/Oncology
      Member
    • American Society of Human Genetics
      Member
    • Children’s Oncology Group
      Member

    Selected Publications

    Pappo, A.S., Russell, H.V., Kornguth, D.G., Nuchtern, J.G., & Wang, L.L. (2008). Ch. 50.2 Cancers of Childhood, Solid Tumors of Childhood. In: DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology, 8th edition. (Eds. Vincent DeVita, Jr., Theodore S. Lawrence, Steven A. Rosenberg) Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008: 2043-2083.

    Mehollin-Ray, AR, Kozinetz CA, Schlesinger AE, Guillerman RP, Wang LL. Radiographic Abnormalities and Genotype-Phenotype Correlation with RECQL4 Mutation Status in Rothmund-Thomson Syndrome. American Journal of Roentgenology 2008 Aug;191(2):W62-6.

    Hicks MJ, Roth J, Kozinetz CA, Wang LL. Clinicopathologic Features of Osteosarcoma in Patients with Rothmund-Thomson Syndrome. Journal of Clinical Oncology 2007; 25:370-375.

    Wang, LL. Biology of Osteogenic Sarcoma. Cancer Journal 2005; 11(4): 294-305.

    Wang, LL, Chintagumpala, M, Gebhardt, M. Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology. In: UpToDate, Basow, D (Ed), UpToDate, Waltham, MA 2009. Available at http://www.uptodate.com.

    * Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.

Share email